Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVE: Lysergic acid diethylamide (LSD) is used recreationally and in clinical research. The aim of the present study was to characterize the pharmacokinetics and exposure-response relationship of oral LSD. METHODS: We analyzed pharmacokinetic data from two published placebo-controlled, double-blind, cross-over studies using oral administration of LSD 100 and 200 µg in 24 and 16 subjects, respectively. The pharmacokinetics of the 100-µg dose is shown for the first time and data for the 200-µg dose were reanalyzed and included. Plasma concentrations of LSD, subjective effects, and vital signs were repeatedly assessed. Pharmacokinetic parameters were determined using compartmental modeling. Concentration-effect relationships were described using pharmacokinetic-pharmacodynamic modeling. RESULTS: Geometric mean (95% confidence interval) maximum plasma concentration values of 1.3 (1.2-1.9) and 3.1 (2.6-4.0) ng/mL were reached 1.4 and 1.5 h after administration of 100 and 200 µg LSD, respectively. The plasma half-life was 2.6 h (2.2-3.4 h). The subjective effects lasted (mean ± standard deviation) 8.2 ± 2.1 and 11.6 ± 1.7 h for the 100- and 200-µg LSD doses, respectively. Subjective peak effects were reached 2.8 and 2.5 h after administration of LSD 100 and 200 µg, respectively. A close relationship was observed between the LSD concentration and subjective response within subjects, with moderate counterclockwise hysteresis. Half-maximal effective concentration values were in the range of 1 ng/mL. No correlations were found between plasma LSD concentrations and the effects of LSD across subjects at or near maximum plasma concentration and within dose groups. CONCLUSIONS: The present pharmacokinetic data are important for the evaluation of clinical study findings (e.g., functional magnetic resonance imaging studies) and the interpretation of LSD intoxication. Oral LSD presented dose-proportional pharmacokinetics and first-order elimination up to 12 h. The effects of LSD were related to changes in plasma concentrations over time, with no evidence of acute tolerance. TRIAL REGISTRATION: NCT02308969, NCT01878942.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LSD (1, 100 µg) attained a maximal plasma concentration of 4 nM at two hours after oral administration in healthy volunteers, and declined thereafter with an approximately four hour half-life [99].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [99]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The subjective effects, both good and bad, closely tracked the plasma concentrations, as did physiological responses, such as heart rate and blood pressure increases.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“The pharmacokinetics of oral LSD (1) (100 and 200 µg) in human subjects indicated a mean plasma half-life of 2–6 h and a persistently close relationship between the individual LSD (1) concentration in plasma and the magnitude of subjective response within subjects, with moderate counterclockwise hysteresis during the 12 h after dosing [99].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine
Sheiner, L. B., Stanski, D. R., Vozeh, S., Miller, R. D., & Ham, J. (1979) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1979253358 · Cited by 1,134
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859 · cited 7×
“Magnetic resonance imaging scanning correctly started at approximately 70 and 150 min in the studies that used intravenous [13] and oral (unpublished data from Study 1, 100 lg) routes of LSD administration, respectively, coinciding with the maximal response to LSD.”
InfluentialGasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · cited 2×
“The 200-lg dose preparation of LSD has been used in patients [5, 6], and the present phase I study provides the pharmacokinetic data for these phase II studies.”
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Increased global functional connectivity correlates with LSD-induced ego dissolution
Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., Laufs, H., Leech, R., McGonigle, J., Crossley, N., et al. (2016) · Current Biology · doi:10.1016/j.cub.2016.02.010 · Cited by 503 · cited 1×
“In contrast, no data are currently available on the plasma concentrations of LSD after intravenous administration of 75 lg of LSD base in saline [11], despite the publication of extensive pharmacodynamic data using this preparation and route of administration [10–19].”
Gasser, P., Kirchner, K., & Passie, T. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114555249 · Cited by 456 · cited 1×
“The 200-lg dose preparation of LSD has been used in patients [5, 6], and the present phase I study provides the pharmacokinetic data for these phase II studies.”
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455 · cited 2×
“Both doses were within the range of doses that are taken for recreational purposes [1].”
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 411 · cited 1×
“The LSD-induced subjective and autonomic effects were determined as a difference from placebo in the same subject at the corresponding time point to control for circadian changes and placebo effects [22].”
Self-citation
Research works printed but not linked: 1
- Hoch PH. Studies in routes of administration and counteracting drugs: lysergic acid diethylmide and mescaline in experimental psychosis. New York: Grune and Stratton; 1956.
Cited by
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269
Effects of psilocybin therapy on personality structure
Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart‐Harris, R. L. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12904 · Cited by 267
“Intriguingly, the treatment effect in these trials appears to last for several months – much longer than the pharmacological presence of the actual compounds (25, 26).”
BackgroundDistinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0569-3 · Cited by 247
Self-citationHolze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., Duthaler, U., Varghese, N., Eckert, A., Borgwardt, S., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00883-6 · Cited by 245
Self-citation
Metadata
- Authors
- Dolder, P. C., Schmid, Y., Steuer, A. E., Kraemer, T., Rentsch, K. M., Hammann, F., & Liechti, M. E.
- Affiliations
- University Hospital of Basel (CH)
- University of Zurich (CH)
- Corresponding author
- Liechti, Matthias E.
- ORCID
- Venue
- Clinical Pharmacokinetics
- Published
- 2017-02-14
- Volume
- 56
- Issue
- 10
- Pages
- 1219-1230
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC5591798
- OpenAlex
- W2589071607
- Cited by
- 133
- References
- 42
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 14 · 2023: 19 · 2022: 23 · 2021: 20 · 2020: 14 · 2019: 9 · 2018: 7 · 2017: 4
- FWCI
- 11.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- edoc (University of Basel) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_170249)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Keywords
- lysergic acid diethylamide, LSD, pharmacokinetics, pharmacodynamics, oral administration, exposure-response relationship, subjective effects, plasma concentration, dose proportionality, first-order elimination, acute tolerance, psychedelics, hysteresis, vital signs, healthy volunteers, compartmental modeling, pharmacokinetic-pharmacodynamic modeling
- MeSH terms
- Administration, Oral, Adult, Affect, Blood Pressure, Dose-Response Relationship, Drug, Double-Blind Method, Female, Half-Life, Hallucinogens, Heart Rate, Humans, Lysergic Acid Diethylamide, Male, Middle Aged, Cross-Over Studies, Young Adult, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects. https://app.cochat.ai/papers/10.1007/s40262-017-0513-9
- The paper
- Dolder, P. C., Schmid, Y., Steuer, A. E., Kraemer, T., Rentsch, K. M., Hammann, F., & Liechti, M. E. (2017). Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-017-0513-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.